EVE Investment (ASX:EVE) - Managing Director, Bill Fry - The Market Herald
Managing Director, Bill Fry
Source: EVE Investment
  • EVE Investments (EVE) has announced record results, increasing both its revenue and cash balance during the September quarter
  • Group unaudited revenues grew 23 per cent compared to the June quarter, to total $2.1 million - more than half of which comes from the U.S.
  • Additionally, EVE increased its cash balance from $5.1 million to $5.4 million in Q1 FY21
  • The company said the positive results come as global demand grows for its honey and tea tree products
  • Looking ahead, EVE advised it was on track for a bumper tea tree oil yield which will exceed the previous year's harvest
  • It's also planning to use the record start to FY21 to commence sales in the U.K., Canada, Japan and Singapore
  • Shares in EVE have ended the day steady, worth 1.2 cents

Wellness business EVE Investments (EVE) has announced a record start to FY21, increasing both its revenue and cash balance during the September quarter.

The ASX‐listed health, nutrition and wellness company reported group unaudited revenues of $2.1 million, a 23 per cent increase on the June quarter results and a 50 per cent increase on March's figures.

EVE also managed to increase its cash balance from $5.1 million at the end of Q4 FY20 to $5.4 million at the end of Q1 FY21.

Additionally, the wellness group's inventory increased to $900,000, with receivables totalling $600,000 at the end of the quarter.

The strong results are all being attributed to the growing demand for EVE's various honey and tea tree oil products.

The company's Meluka Australia brand had two of its native honey shipments sell out prior to arriving in China, where they were being sold.

As a result of the demand, an additional sea container of 21,120 units of native raw honey, as well as an initial 2112 units of tea tree honey, was sent to the region this quarter.

EVE said its tea tree products were continuing to be popular, as COVID-19 prompted customers to take note of the product's antibacterial properties.

The company said demand for tea tree oil was so high, it was outstripping its supply and forcing it to bring in third party suppliers.

Pleasingly though, EVE reports it is on track to yield 10 per cent more tea tree oil than last year — as it continues its annual harvest from Jenbrook’s plantation.

Almost five tonnes of organic tea tree oil have been produced from June to September, with harvesting to be completed in the coming weeks.

Going forward, EVE is planning to use its record start to FY21 to commence sales in the U.K., Canada, Japan and Singapore.

The company has already expanded to Taiwan, launching in July via the sale of its Meluka Australia’s honey and tea tree honey products.

EVE also sells its oils to the U.S. - with the region making up over half of all the $2.1 million in group revenue brought in this quarter.

"The interest in our products from Chinese and Taiwanese consumers was particularly pleasing and bodes well for the introduction of our other products into these regions," EVE Managing Director Bill Fry said on the September quarter results.

"In addition, the success of our native raw honey product on Amazon is paving the way for our other honey products and the probiotic concentrates on this channel. This is a key strategy we aim to replicate across all regions where we utilise Amazon," Bill added.

Shares in EVE Investments have ended today's trading session trading steady at 1.2 cents each.


EVE by the numbers
More From The Market Herald
Keytone Dairy milks positive half year results for future growth

" Keytone Dairy (ASX:KTD) triples profits in 1H FY21 amid record sales growth

Food producer Keytone Dairy (KTD) has released its half-yearly accounts, revealing it managed to triple its profits during the period.
ImpediMed (ASX:IPD) - Managing Director & CEO, Rick Carreon - The Market Herald

" Impedimed’s (ASX:IPD) screening tech proves effective against BCRL

A data meta-analysis shows Impedimed’s (IPD) spectroscopy technology can reduce incidence rates of chronic breast cancer-related lymphoedema (BCRL).
Creso Pharma (ASX:CPH)  to benefit from new CBD E.U. ruling

" Creso Pharma (ASX:CPH) to benefit from new CBD E.U. ruling

Creso Pharma (CPH) shares are rising after a new ruling on cannabidiol (CBD) products, unlocking major potential for the company in Europe.
Telix Pharmaceuticals (ASX:TLX) - CEO, Dr Christian Behrenbruch - The Market Herald

" Telix Pharmaceuticals (ASX:TLX) eyes TheraPharma buy

Telix Pharmaceuticals (TLX) is set to buy Swiss-German biotech TheraPharm for €10.2 million (around A$16.5 million) upfront.